

TAIH

Generating Innovation with Japan: BC 2021 - HealthTech

Taiho Pharmaceutical

Robert Tam, Director, Market Access March 9, 2021



JETRO

Japan External Trade Organization

TAIHO PHARMACEUTICAL CO., LTD.




Corporate Philosophy


We strive to improve human health and contribute to a society enriched by smiles



Company Profile

Taiho Pharmaceutical, co. ltd





Offices and Facilities

Head Office/Tokyo		Branch Offices	: 15
Pharmaceutical value che	 Headquarter functions Clinical development QA Medical affairs Marketing 	 Ethical drug: 15 Consumer: 7 	
Drug Discovery	Drug Development	Manufacturing Sale	s & Marketing
Research Institute: 2	e Pla	nts: 4	
	ba et identification optimization	Saitama (API) U.S. Inspection European authorities Inspection	Tokushima (Products) U.S. Inspection European authorities Inspection
Tokus	hima	Kitajima (Products)	Inuyama (API)

- Pre-clinical studies
- CMC development




U.S. Inspection European authorities Inspection OSDrC Tec

on



3

Taiho Subsidiary Companies




Otsuka Group Profile

 ▶ 189 companies (162 subsidiaries and 26 affiliates , plus 1 company (Otsuka Holdings itself))

- About **47,000** employees
- Global network: JP, Asia, MEA, Oceania, EU, NA, LA (as of December 31, 2018)

Structure of Group Capital



Nutraceuticals = nutrition + pharmaceuticals

Taiho is a **wholly owned subsidiary** of Otsuka HD. Otsuka HD also holds a **100%** share of **6 other companies**.

(as of December 31, 2018)

TAIHO PHARMACEUTICAL CO., LTD.

5



North America Holdings



Otsuka Otsuka Holdings Co., Ltd.











Sticking to your needs











Cambridge Isotope Laboratories, Inc.

Enriching Scientific Discovery

. . .

Our Business Focus



Gastrointestinal Diseases

(Gastrointestinal tract and related organs)

- Cancer & Supportive care
- Unmet medical needs

Products: Lonsurf, Abraxane, Aloxi, TS-1, Uzel



Dermatology and Otolaryngology

(Skin, Nose, Ear, and related organs)

- Allergy - Psoriasis & Dermatitis

Products: Bilanoa, Tremfya, Methaderm, IPD



Pulmonary Diseases

(Lung, Bronchi, and related organs)

- Cancer & Supportive care
- Inflammatory Diseases

Products: Abraxane, Aloxi, TS-1, Keytruda



Other Diseases

(Mammary gland, Bladder and other organs)

- Cancer & Supportive care
- Urination Dysfunctions
- Rare Cancers & diseases

Products: Abraxane, Aloxi, TS-1, Zolinza, Yondelis

TAIHO PHARMACEUTICAL CO., LTD.

Taiho Businesses

Oncology Products

Lonsurf





TS-1

Anti-cancer agent

Anti-cancer agent

Anti-cancer agent

11/11. 5

1 215492 1 215492

100

Abraxane

Aloxi



Supportive Care

UFT UZEL Zolinza Yondelis E-fen & others

Allergy & Dermatology Products and Others

Bilanoa



Allergy



IPD

Allergy

Methaderm




Dermatology

Zosyn



Antibiotic



Tremfya

8

Co-promotion with Janssen











HarnCare **PITAS** & others




Business Development...



Pipeline (Major Products)

	Products	ΜΟΑ	Indication	Preclinic al	Ph 1	Ph 2	Ph 3	Development Locations	Partnering Status	
	TAS-115	VEGR/PDGFR inhibitor	Osteosarcoma					JP		
	TAS-116	HSP90 inhibitor	GIST					JP		
	TAS-120 Futibatinib	FGFR inhibitor	Cholangiocarcinoma			# HE	LSINN	JP,US,EU		
Лбс	Pro-NETU	NK1RA	Chemotherapy-induced Nausea & Vomiting					JP	In-licensed from Helsinn Taiho Territory: JPN	
Oncology	TAS-117	Allosteric Akt inhibitor	Solid Tumor		R		*US studies are nducted by Arcus	JP		
ō	AB122 Zimberelimab	Anti-PD1 mAb	NSCLC, CRC, Pancreas, TNBC		R		*US studies are nducted by Arcus	US*	In-licensed from Arcus Taiho Territory: JPN & Asia (ex China)	
	AB928 Etruma- denant	A2R Antagonist	NSCLC, CRC, Pancreas, TNBC		cullinan	*US studies are ducted by Cullina		US*	In-licensed from Arcus Taiho Territory: JPN & Asia (ex China)	
	TAS3681	AR Antagonist	Prostate Cancer		LSINN			US, EU		
	TAS6417 CLN081	EGFR inhibitor	NSCLC		pharmaceutic	X° 📀 MSD		US*, JP	Out-licensed to Cullinan Pearl Taiho Territory: JPN	
>	TAS0953 нмоб	RET inhibitor	Solid Tumor					-	Out-licensed to Helsinn	
Non-Oncology	RAS and SHP2	RAS and SHP2 inhibitors	Solid Tumor			meiji		-	Collaboration with Astex and MSD MSD exercised the option of SHP2 inhibitor	
lon-O	TAS-205	Prostaglandin D2 synthase inhibitor	Duchenne Muscular Dystrophy					JP		
	TAS-115	VEGR/PDGFR inhibitor	Idiopathic pulmonary fibrosis					JP		
10	TAC-302	Neuroprotective Agent	Overactive Bladder					TAIHO	DIPHARMACEUTIGALCO.,	LTD.

Major Collaborations



Key BD Transactions in past 5 years

In-license

LTI-01 (single-chain urokinase plasminogen activator): Lung Therapeutics, 2020 Zimberelimab/AB122 (anti-PD-1 antibody): Arcus Biosciences, 2020 Etrumadenant/AB928 (A2R Antagonist): Arcus Biosciences, 2018 Tremfya (anti-IL-23 antibody, *co-promotion*): Janssen, 2017 Keytruda (anti-PD1 antibody, *co-promotion*): MSD, 2016-2019

Out-license

RAS and SHP2 Programs (Research Collaboration): ASTEX and MSD, 2020 TAS-119/VIC-1911 (Aurora A inhibitor): VITRAC Therapeutics, 2019 TAS6417/CLN-081 (EGFR inhibitor): Cullinan Pearl, 2019 TAS0953/HM06 (RET inhibitor): Helsinn, 2017



Seeking investments in <u>early stage preclinical oncology</u> as well as <u>platform technology companies</u> for our core therapeutic areas. We will review the wide variety of modalities (both <u>biologics and small molecules</u>) and opportunities mainly in <u>North America and Europe</u>. We will also consider the option-type of investments and spin-outs, in addition to pure equity investments.

Inception	2016
Business	Investment into Global Biotech Ventures
Office	Menlo Park, CA
Investment Pool	\$300M
Report Line	Global Chief Corporate Officer
Goal of Investment	Strategic Benefits > Financial Returns

Strategic Benefits:

- Invest in promising biotech ventures with potential alliance opportunities in the near future
- Access to new biology candidates beyond Internal R&D
- Option Investment including establishing Build to Buy opportunities
- **C**reate spin-out companies using Taiho pipeline programs

Investment Sectors:

- Drug Discovery (1st-in-class or New biology based approach)
- Innovative Platform Technologies for Drug Discovery
- Spin-out Opportunities from Taiho Pipelines
- Medical Device/Diagnostics/Digital Health (opportunistic)

Therapeutic areas:

- Oncology
- Non-oncology (Immunology/Allergy/Bone/Muscle/Orphan)

Modality:

- Small molecules
- Biologics/Oncolytic virus
- Gene/Cell Therapy

Stage:


- Research to Pre-IND
- IND to PoC (opportunistic)

Region:

• Mainly NA, EU and Japan



Taiho Ventures Interest in Oncology and Portfolio



Autophagy

Actively seeking new science in oncology!



Research Collaboration with X-Chem Initiated by Taiho Ventures



X-Chem Pharmaceuticals, Inc 100 Beaver St Waltham, MA 02453, USA

X-Chem Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical using DEX[™] Technology

Goal to Establish Novel Small Molecule Leads Using X-Chem's Discovery Engine Fueled by its
 Proprietary Library of More Than 120 Billion DNA-Encoded Compounds –

 Partnership, which will be X-Chem's first collaboration in Japan, could be worth up to \$352 million plus royalties –

WALTHAM, Mass. – December 20, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem's DEX[™] technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of the collaboration is to discover innovative lead structures for complex drug targets in multiple therapeutic areas with unmet medical need.



Innovative R&D Collaboration with Arcus Biosciences (a Taiho Ventures portfolio)

Innovative deal structure: Term Sheet negotiated by Taiho Ventures Opted in AB928 (A_{2a}R and A_{2b}R dual antagonist) in 2018

Arcus Biosciences Announces Option and License Agre Taiho Pharmaceutical Co. Ltd.



September 19, 2017 09:30 PM Eastern Daylight Time

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it has entered into an option and license agreement with Taiho Pharmaceutical Co. Ltd., for the potential development and commercialization of product candidates in Arcus's portfolio in Japan and certain other territories in Asia (excluding China).

"We founded Arcus in 2015 to create a broad portfolio of novel molecules that target the most prevalent mechanisms of tumor-induced immunosuppression"

🔰 Tweet this

"We founded Arcus in 2015 to create a broad portfolio of novel molecules that target the most prevalent mechanisms of tumor-induced immunosuppression," said <u>Terry Rosen</u>. Arcus's CEO. "Our relationship with TAIHO began with the inaugural investment of Taiho Ventures in Arcus in 2016, and since that time, we have come to recognize an alignment in vision with TAIHO. We are thrilled to collaborate with TAIHO on the advancement of our rapidly growing pipeline for the benefit of patients in Japan and other important territories in Asia. Given its significant expertise in the oncology area, we are confident that TAIHO will maximize the value of our programs in these regions. We look forward to advancing at least

four immuno-oncology product candidates into clinical development by the end of 2018."

Based on the terms of the agreement, Arcus will receive \$35mm in payments during the first three years of the agreement. In return for these payments, TAIHO will receive an option to in-license the development and commercialization rights in its region to clinical stage product candidates from Arcus's portfolio over a five-year term. For any product candidate for which TAIHO exercises a license, Arcus will receive an option payment and is eligible to receive up to \$275mm in development, regulatory and commercial milestone payments per molecule. Arcus is also eligible to receive royalties on the net sales of each product



Spin-out activities using Taiho molecules





February 5, 2019 Taiho Pharmaceutical Co., Ltd. Cullinan Oncology, LLC

Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration

to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor

-FIH Study in EGFR Exon 20 Insertions Will Commence in 2019-

Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor discovered by Taiho Pharmaceutical.

Under the terms of the agreement, Taiho Pharmaceutical will grant an exclusive, global license ex-Japan for the development and commercialization of TAS6417 to Cullinan Pearl, a newly formed USbased company under the Cullinan Oncology umbrella. Taiho Pharmaceutical will receive an upfront payment, regulatory and sales milestones, as well as royalties based on net sales. Taiho Ventures, LLC, a strategic corporate venture arm of Taiho Pharmaceutical, alongside Cullinan Oncology, will provide funding for Cullinan Pearl's Series A.

Otsuka	Investment	in	BC's	Aurinia

THE GLOBE AND MAIL*	REPOR	T ON BUS	INESS									MEMBER BENE	FITS	BOB TAM1	Q	AdChoices
ADA WOI	RLD BU	SINESS	INVESTING	OPINION	POLITICS	SPORTS	LIFE	ARTS	DRIVE	REAL ESTATE	WATCHLIST					
								Ad clo	sed by	Google						
		(. 19				·	0	1 1	l .				
												biotech	as	B.C.'s		urinia
		get	s FD.	A gr	een	ligh	it t	0 S	ell	new l	upus	drug				
			COFF > TECHN		ORTER							TR	ENDIN	G		
		UPDATED	D JANUARY 22 JANUARY 25, SCRIBERS									1				Canada: How
				CHARE							-4	1		COVID-19 cri denly last Ma		alated
			JMMENTS V	SHARE	-A AT	IEXT SIZE		SOOKMAN	(K		•••	0				
		\bigcirc	•					0	0:00	Voice 1x	×	2	opin Erin		a long	way to go to
														ve he's ready N IBBITSON	to be I	РМ 🚥
			Pharmace			•••				6						
			istration to an biotechi		-	evere form	n of lu	ipus, a	rare mi	lestone for a		3	OPIN	lion	o worl	d took away
		Canadi		1010gy (0)	mpany.								Ten	i vears and th	ne wor	d took awa

News / Events	Aurinia Announces Collaboration and
Overview	Licensing Agreement with Otsuka
Press Releases	Pharmaceutical Co., Ltd. for the Development and Commercialization
IR Calendar	of Voclosporin in Europe and Japan
Email Alerts	

Overview News / Events Company Info Financial Info Stock Data SEC Filings Governance and Documents

DECEMBER 17, 2020

Aurinia

2020 Notice & Access

- Aurinia to receive \$50 million U.S. upfront payment in addition to up to \$50 million U.S. in regulatory and reimbursement milestone payments -

- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -

Investors & Media Careers Contact Us

Investor Tools

IN DOWNLOAD AS PDP

About Us Our Focus Our Medicine For Patients/Physicians

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company") today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.

As part of the agreement, Aurinia will receive an upfront cash payment of \$50 million U.S. and has the potential to receive up to \$50 million U.S. in regulatory and reimbursement milestone payments. Aurinia will receive tiered royalties ranging from 10 to 20 percent (dependent on achievement of sale milestones) on net sales upon commercialization, along with additional milestone payments based on the attainment of certain annual sales by Otsuka.

Voclosporin is a novel, investigational, orally administered treatment developed to treat patients with LN, a chronic, progressive inflammation of the kidneys that is one of the most serious complications of the autoimmune disease systemic lupus erythematosus (SLE).

The agreement leverages Otsuka's well-recognized expertise in rare kidney diseases to underscore Aurinia's commitment to expanding global access to voclosporin for the treatment of LN. Otsuka expects to file a marketing authorization application (MAA) with the European Medicines Agency (EMA) in Q2 2021 and will also manage the filing of voclosporin for LN with Pharmaceuticals Medical Devices Agency (PDMA) in Japan at a later date. Voclosporin is currently under review with the U.S. Food and Drug Administration (FDA) with an assigned Prescription Drug User Fee Act (PDUFA) target action date of January 22, 2021.

"Otsuka, with strong capabilities in nephrology and rare disease, is an ideal strategic partner to introduce voclosporin in Europe and Japan," says Peter Greenleaf, President and Chief Executive Officer, Aurinia Pharmaceuticals. "This collaboration will provide Aurinia with additional non-dilutive funds to focus on the successful U.S. launch of voclosporin and support plans to build our pipeline, while ensuring more lupus nephritis patients around the world can benefit from this potentially life-saving medication."

Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., Ltd. commented, "Effective treatments for lupus nephritis are currently limited and a new treatment option such as voclosporin would be welcomed. We are pleased to enter the collaboration with Aurinia and look forward to delivering this drug to patients in Japan and Europe."

About Lupus Nephritis

LN is an inflammation of the kidney caused by SLE and represents a serious progression of SLE. SLE is a chronic, complex and often disabling disorder. The disease is highly heterogeneous, affecting a wide range of organs and tissue systems. Unlike SLE, LN has straightforward disease outcomes, where an early reduction in proteinuria correlates with positive long-term outcomes. In patients with LN, renal damage results in proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced eGFR, and increased serum creatinine levels. LN is debilitating and costly and if poorly controlled, LN can lead to permanent and



TAIHO PHARMACEUTICAL CO., LTD.

20